SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
01/07/2026 08:00 AM • SAB Biotherapeutics announced the appointment of David Zaccardelli, Pharm.D. as Board Chair and Rita Jain, M.D. as an independent director, effective immediately. Zaccardelli brings over 20 years of biopharmaceutical executive experience, including leading the successful launch of Ohtuvayre® at Verona Pharma. Jain is a rheumatologist with two decades of experience in biopharmaceutical development and clinical strategy. Both appointments are intended to support the company's advancement of SAB-142, its lead candidate for Type 1 Diabetes treatment, through clinical development and potential commercialization.
SABS - The appointment of experienced executives with strong track records in biotech leadership and drug development signals confidence in the company's direction and potential. Zaccardelli's success with major product launches and Jain's expertise in autoimmune disease development strengthen the company's leadership for advancing SAB-142 through clinical trials and commercialization, indicating positive momentum for the company's growth trajectory.
Investing.com • Gurufocus